News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
739,043 Results
Type
Article (42103)
Company Profile (259)
Press Release (696669)
Multimedia
Podcasts (110)
Webinars (21)
Section
Business (206044)
Career Advice (2051)
Deals (35782)
Drug Delivery (136)
Drug Development (81890)
Employer Resources (173)
FDA (16590)
Job Trends (15077)
News (348620)
Policy (32899)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2631)
Accelerated approval (55)
ADA (44)
Adcomms (29)
Allergies (193)
Alliances (49953)
ALS (227)
Alzheimer's disease (1852)
Antibody-drug conjugate (ADC) (531)
Approvals (17072)
Artificial intelligence (737)
ASCO (330)
Autoimmune disease (348)
Automation (63)
Bankruptcy (367)
Best Places to Work (11674)
BIO (70)
BIOSECURE Act (21)
Biosimilars (237)
Biotechnology (164)
Bladder cancer (205)
Brain cancer (75)
Breast cancer (806)
Cancer (6360)
Cardiovascular disease (507)
Career advice (1747)
Career pathing (45)
CAR-T (358)
CDC (59)
Celiac Disease (3)
Cell therapy (976)
Cervical cancer (56)
Clinical research (71764)
Collaboration (2238)
Commercialization (1)
Company closure (5)
Compensation (1522)
Complete response letters (85)
COVID-19 (2772)
CRISPR (117)
C-suite (1256)
Cystic fibrosis (159)
Data (8686)
Decentralized trials (3)
Denatured (38)
Depression (176)
Dermatology (98)
Diabetes (668)
Diagnostics (7063)
Digital health (64)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (369)
Drug pricing (205)
Drug shortages (31)
Duchenne muscular dystrophy (308)
Earnings (92434)
Editorial (69)
Employer branding (21)
Employer resources (155)
Events (122010)
Executive appointments (1141)
FDA (20641)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (22)
Frontotemporal dementia (35)
Funding (1877)
Gene editing (250)
Generative AI (62)
Gene therapy (756)
GLP-1 (1100)
Government (4778)
Grass and pollen (6)
Guidances (422)
Healthcare (19203)
Hematology (192)
HIV (90)
Huntington's disease (63)
IgA nephropathy (113)
Immunology and inflammation (310)
Immuno-oncology (111)
Indications (222)
Infectious disease (3144)
Inflammatory bowel disease (226)
Inflation Reduction Act (16)
Influenza (143)
Intellectual property (321)
Interviews (321)
IPO (16721)
IRA (52)
Job creations (3688)
Job search strategy (1446)
JPM (58)
Kidney cancer (21)
Labor market (112)
Layoffs (587)
Leadership (42)
Legal (7998)
Liver cancer (103)
Longevity (36)
Lung cancer (846)
Lymphoma (477)
Machine learning (65)
Management (61)
Manufacturing (1165)
Marketing (4)
MASH (211)
Medical affairs (1)
Medical device (14023)
Medtech (14198)
Mergers & acquisitions (20378)
Metabolic disorders (1659)
mRNA (235)
Multiple sclerosis (200)
NASH (17)
Neurodegenerative disease (463)
Neuropsychiatric disorders (110)
Neuroscience (3497)
Neurotech (1)
NextGen: Class of 2026 (6582)
Non-profit (4564)
Now hiring (83)
Obesity (763)
Opinion (302)
Ovarian cancer (242)
Pain (267)
Pancreatic cancer (357)
Parkinson's disease (395)
Partnered (38)
Patents (644)
Patient recruitment (777)
Peanut (67)
People (60341)
Pharmaceutical (56)
Pharmacy benefit managers (33)
Phase 1 (22397)
Phase 2 (31629)
Phase 3 (23515)
Pipeline (9922)
Policy (335)
Postmarket research (2572)
Preclinical (9520)
Press Release (64)
Prostate cancer (337)
Psychedelics (57)
Radiopharmaceuticals (349)
Rare diseases (1194)
Real estate (6025)
Recruiting (71)
Regulatory (25951)
Reports (56)
Research institute (2441)
Resumes & cover letters (355)
Rett syndrome (46)
RNA editing (28)
RSV (90)
Schizophrenia (183)
Series A (323)
Series B (236)
Service/supplier (12)
Sickle cell disease (121)
Special edition (26)
Spinal muscular atrophy (169)
Sponsored (48)
Startups (3708)
State (2)
Stomach cancer (18)
Supply chain (134)
Tariffs (88)
The Weekly (70)
Vaccines (1159)
Venture capital (123)
Weight loss (488)
Women's health (138)
Worklife (21)
Date
Today (64)
Last 7 days (515)
Last 30 days (2268)
Last 365 days (30578)
2026 (16517)
2025 (30369)
2024 (35336)
2023 (40229)
2022 (51341)
2021 (55893)
2020 (54200)
2019 (46748)
2018 (35204)
2017 (32280)
2016 (31728)
2015 (37778)
2014 (31502)
2013 (26537)
2012 (28838)
2011 (29486)
2010 (27603)
Location
Africa (749)
Alabama (93)
Alaska (7)
Arizona (367)
Arkansas (14)
Asia (40278)
Australia (6615)
California (14115)
Canada (3980)
China (1506)
Colorado (602)
Connecticut (613)
Delaware (435)
Europe (87269)
Florida (2123)
Georgia (448)
Hawaii (3)
Idaho (64)
Illinois (1159)
India (99)
Indiana (635)
Iowa (25)
Japan (602)
Kansas (135)
Kentucky (51)
Louisiana (58)
Maine (76)
Maryland (1672)
Massachusetts (10118)
Michigan (377)
Minnesota (763)
Mississippi (6)
Missouri (149)
Montana (33)
Nebraska (30)
Nevada (151)
New Hampshire (86)
New Jersey (3685)
New Mexico (30)
New York (3699)
North Carolina (1774)
North Dakota (9)
Northern California (7133)
Ohio (423)
Oklahoma (23)
Oregon (43)
Pennsylvania (2793)
Puerto Rico (31)
Rhode Island (52)
South America (1120)
South Carolina (87)
South Dakota (2)
Southern California (5596)
Tennessee (232)
Texas (2267)
United States (49729)
Utah (419)
Vermont (2)
Virginia (345)
Washington D.C. (82)
Washington State (1124)
West Virginia (4)
Wisconsin (132)
Wyoming (2)
739,043 Results for "summit biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
June 29, 2026
·
4 min read
Immuno-oncology
Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers
As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.
May 29, 2026
·
4 min read
·
Annalee Armstrong
Immuno-oncology
ASCO: Summit reached with China lung data but new climb begins to prove global benefit
“King Keytruda’s reign continues,” analysts at BMO Capital Markets declared after Chinese data for Summit Therapeutics’ ivonescimab were revealed at the American Society for Clinical Oncology in Chicago.
June 1, 2026
·
3 min read
·
Annalee Armstrong
Press Releases
Trethera To Present Optic Neuritis Research at Los Angeles Bioscience Ecosystem Summit 2026
May 6, 2026
·
5 min read
Press Releases
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
April 7, 2026
·
5 min read
Press Releases
Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
April 23, 2026
·
5 min read
Immuno-oncology
ASCO: Akeso’s VEGF/PD-1 boosts lung cancer survival, relieving pressure on US partner Summit
Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous data from Akeso’s HARMONi-6 trial left them wanting.
May 31, 2026
·
3 min read
·
Annalee Armstrong
Lung cancer
Summit shares descend as PD-1/VEGF asset misses early survival mark
Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement—but the early analysis delivered disappointment for the company and shareholders.
May 4, 2026
·
2 min read
·
Tristan Manalac
Lung cancer
Merck’s early PD-1/VEGF data competitive in lung cancer, but Summit ‘looms large’
While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 readout in non-small cell lung cancer still leaves analysts with some questions moving into later-stage development.
April 20, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 8, 2026
·
1 min read
1 of 73,905
Next
